Lupin said it has received USFDA approval for its generic version of anti-depressant.
The tentative approval by the United States Food and Drug Administration (USFDA) is for multiple strengths of 12.5 mg, 25 mg and 37.5 mg of the generic version of Apotex Technologies' Paxil CR tablets of similar strengths, Lupin said in a BSE filing.
The drug is indicated for treatment of major depressive disorder, panic disorder, social anxiety disorder and premenstrual dysphoric disorder.
Citing IMS MAT data till June 2016, Lupin said Paxil CR had US sales of USD 127.4 million.
Shares of Lupin were trading at Rs 1,524.70, up 0.14 per cent in the afternoon trade on BSE.
(This story has not been edited by NDTV staff and is auto-generated from a syndicated feed.)
